A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy

Trial Profile

A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Vistusertib (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 16 Jan 2018 Planned End Date changed from 1 Oct 2017 to 1 Feb 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results analysing pharmacodynamic biomarker effects of vistusertib given prior to radical prostatectomy and safety presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top